87 related articles for article (PubMed ID: 22552811)
21. 17q12-21 - the pursuit of targeted therapy in breast cancer.
Glynn RW; Miller N; Kerin MJ
Cancer Treat Rev; 2010 May; 36(3):224-9. PubMed ID: 20100636
[TBL] [Abstract][Full Text] [Related]
22. Cox-2 and Her2/neu co-expression in invasive bladder cancer.
Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L
Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
Shiu LY; Liang CH; Huang YS; Sheu HM; Kuo KW
Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
[TBL] [Abstract][Full Text] [Related]
24. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
25. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis and co-expressed of ER and c-erbB-2 (HER2/neu) protein in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2008; 49(4):469-78. PubMed ID: 19050794
[TBL] [Abstract][Full Text] [Related]
27. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.
Munzone E; Nolé F; Goldhirsch A; Botteri E; Esposito A; Zorzino L; Curigliano G; Minchella I; Adamoli L; Cassatella MC; Casadio C; Sandri MT
Clin Breast Cancer; 2010 Oct; 10(5):392-7. PubMed ID: 20920984
[TBL] [Abstract][Full Text] [Related]
28. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
Potemski P; Płuciennik E; Bednarek AK; Kusińska R; Pasz-Walczak G; Jesionek-Kupnicka D; Watala C; Kordek R
Med Sci Monit; 2006 Dec; 12(12):MT57-61. PubMed ID: 17136015
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
Arnason T; Sapp HL; Barnes PJ; Drewniak M; Abdolell M; Rayson D
Neuroendocrinology; 2011; 93(4):249-58. PubMed ID: 21487213
[TBL] [Abstract][Full Text] [Related]
32. HER2/neu expression in relation to clinicopathologic features of breast cancer patients.
Traina A; Agostara B; Marasà L; Calabrò M; Zarcone M; Carruba G
Ann N Y Acad Sci; 2006 Nov; 1089():159-67. PubMed ID: 17261764
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
[TBL] [Abstract][Full Text] [Related]
34. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
35. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
36. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.
Nadler Y; González AM; Camp RL; Rimm DL; Kluger HM; Kluger Y
Ann Oncol; 2010 Mar; 21(3):466-473. PubMed ID: 19717535
[TBL] [Abstract][Full Text] [Related]
37. GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma.
Bivin WW; Yergiyev O; Bunker ML; Silverman JF; Krishnamurti U
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):553-558. PubMed ID: 26945445
[TBL] [Abstract][Full Text] [Related]
38. Context-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines.
Lim RC; Price JT; Wilce JA
Breast Cancer Res Treat; 2014 Feb; 143(3):593-603. PubMed ID: 24464577
[TBL] [Abstract][Full Text] [Related]
39. Epigenetically altered miR‑193a‑3p promotes HER2 positive breast cancer aggressiveness by targeting GRB7.
Tang Y; Yang S; Wang M; Liu D; Liu Y; Zhang Y; Zhang Q
Int J Mol Med; 2019 Jun; 43(6):2352-2360. PubMed ID: 31017268
[TBL] [Abstract][Full Text] [Related]
40. [Bcl-2 as a prognostic factor in different molecular genetic subtypes of breast cancer].
Pavlenko IA; Povilaĭtite PE; Gorelik MZ; Petrov AV
Arkh Patol; 2012; 74(5):36-40. PubMed ID: 23342658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
